Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Evolus ( (EOLS) ) has shared an update.
Evolus terminated its unused at‑the‑market equity sales agreement with Leerink Partners LLC on May 1, 2026, removing a $50 million share issuance facility that had not been tapped and signaling confidence in its current capital position. Earlier, on May 4, 2026, the company reported first‑quarter 2026 net revenue of $73.1 million, up 7% year on year, and delivered its second consecutive quarter of positive adjusted EBITDA, while reaffirming 2026 guidance for double‑digit revenue growth and a low‑ to mid‑single digit adjusted EBITDA margin.
Management highlighted strong Jeuveau® unit growth across U.S. and international markets, rising contribution from Evolysse® and upcoming Estyme® launches, as well as expanding customer accounts and loyalty program participation that support operating leverage. The company also flagged potential exposure to new U.S. tariffs on South Korean patented pharmaceuticals from late 2026 but said product shelf life, manufacturing flexibility and mitigation strategies should limit near‑ to medium‑term impact, underpinning its outlook for sustained growth and improved profitability through 2028.
The most recent analyst rating on (EOLS) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Evolus stock, see the EOLS Stock Forecast page.
Spark’s Take on EOLS Stock
According to Spark, TipRanks’ AI Analyst, EOLS is a Neutral.
The score is held back primarily by weak financial fundamentals (ongoing losses, cash burn, and negative equity/leverage), partially offset by a constructive earnings outlook pointing to 2026 adjusted EBITDA profitability and improving operating leverage. Technical momentum is supportive, while valuation is constrained by the company’s loss-making profile and lack of dividend.
To see Spark’s full report on EOLS stock, click here.
More about Evolus
Evolus, Inc. is a global performance beauty company focused on aesthetic injectable products, targeting next‑generation beauty consumers through a customer‑centric model and digital platform. Its portfolio includes the neurotoxin Jeuveau® and injectable hyaluronic acid gels marketed under the Evolysse® and Estyme® brands, with growing presence in both U.S. and international markets.
Average Trading Volume: 1,042,290
Technical Sentiment Signal: Hold
Current Market Cap: $346.8M
Learn more about EOLS stock on TipRanks’ Stock Analysis page.